Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in a research note issued on Thursday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 1.6 %

Shares of NYSE BTX opened at $1.28 on Thursday. The stock’s 50-day simple moving average is $1.71 and its two-hundred day simple moving average is $1.96. Brooklyn ImmunoTherapeutics has a twelve month low of $0.17 and a twelve month high of $10.10. The firm has a market capitalization of $75.30 million, a P/E ratio of -0.56 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Featured Stories

• Five stocks we like better than Brooklyn ImmunoTherapeutics
• Dividend Capture Strategy: What You Need to Know
• Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
• Consumer Staples Stocks, Explained
• FedEx Stock Dips: Another Reason to Fear Recession Is Near
• EV Stocks and How to Profit from Them
• The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?